ntp-42
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 24, 2021 (NCT04919863)
Timeline
Indications
Mechanism of action
- Thromboxane A2 receptorINHIBITOR
TBXA2R inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)NC(=O)NS(=O)(=O)C1=CC(=CC=C1OC2=CC(=CC=C2)C3=CC=C(OC(F)F)C=C3)C#N- Mol. weight
- 515.529 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS2057H3EG0S ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07193901 | Phase 2 | May 27, 2025 | Government of China |
| NCT06092788 | Phase 1 | Nov 30, 2023 | ATXA Therapeutics Limited, Hammersmith Medicines Research |
| NCT04919863 | Phase 1 | May 24, 2021 | ATXA Therapeutics Limited, Hammersmith Medicines Research |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ATXA Therapeutics Limited | For profit | 2 | 2 | 1 | 2021 |
| Hammersmith Medicines Research | For profit | 2 | 0 | 1 | 2021 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1